Probably because "Biogen offered to buy Sage, its marketing partner on Zurzuvae, a pill to treat postpartum depression, for $469 million — less than the $569 million in cash that Sage has on hand as of September. The lowball offer is unlikely to be accepted, but Sage also has little leverage after a series of clinical failures last year wiped out its research pipeline and decimated its stock price."
Add to My Watchlist
What is My Watchlist?
